Skip Navigation

European Heart Journal 2004 25(2):183-184; doi:10.1016/j.ehj.2003.09.034
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Auer, J.
Right arrow Articles by Eber, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Auer, J.
Right arrow Articles by Eber, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letter to the Editor

Verapamil, atrial fibrillation recurrences and anticoagulation

Johann Auer*, Thomas Weber, Robert Berent and Bernd Eber

Department of Cardiology and Intensive Care, General Hospital Wels, Wels, Austria

* Correspondence to: Dr J. Auer, Department of Cardiology and Intensive Care, Grieskirchnerstraße 42, A-4600 Wels, Austria. Tel: +43 72424152215; Fax: +43 72424153992
E-mail address: johann.auer@khwels.at

Received 26 August 2003; accepted 10 September 2003

The first 10% of the full text of this article appears below.

To the Editor

We read with great interest the paper by de Simone and colleagues1showing that the addition of verapamil to class IC or III antiarrhythmic drugs significantly reduced the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?